The prognosis of patients with mitochondrial myopathies varies greatly, which ultimately depends on the type of disease and degree of involvement of multiple organs. Arginine and carnitine are the most commonly prescribed drugs. Doctors use an integrated combination of 3-6 drugs known as cocktail therapy.
The increased count in cases of mitochondrial myopathies, ongoing clinical trials, rise in the geriatric population, increased number of government initiatives, ease of purchase, investment by R&D in pharmaceutical companies, and availability of healthcare policies are predicted to drive the market growth. The dietary supplement Niacin has recently completed its clinical trial. However, the poor treatment, rise in cost, lack of proper sanitation, side effects associated with the use of prescribed drugs and the risks of other diseases along with mitochondrial myopathies are expected to hinder the market growth. The rise of emerging markets in developing countries, the rise of untapped opportunities, upcoming screening and diagnostic centers, and the rise of novel therapies are the opportunities that are projected to bolster market growth. The lack of expertise, rise in drug recalls, and use of alternatives are the challenges that can hamper the market growth.
Data Bridge Market Research analyses that the mitochondrial myopathies treatment market which was USD 21.5 Million in 2022, would rocket up to USD 36.9 Million by 2030, and is expected to undergo a CAGR of 7.70% during the forecast period. This indicates that the market value. “Genetic Test” dominates the Test type segment of the mitochondrial myopathies treatment market owing to the Increasing prevalence of mitochondrial myopathies. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.